Claims for Patent: 11,814,359

Summary for Patent: 11,814,359

Title:	Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
Abstract:	The present disclosure relates to certain (2,S)-N-[(1,S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof),that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
Inventor(s):	Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan PO KARLSSON, Carl-Johan Aurell, John Fritiof PONTÉN, Kevin James Doyle, Amanda Jane VAN DE POËL, Graham Peter Jones, David Wyn WATSON, Jacqueline Anne MacRitchie, Nicholas John Palmer
Assignee:	Biofocus DPI Ltd , AstraZeneca AB
Application Number:	US17/942,123
Patent Claims:	1. Crystal form A of (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide: having X-ray powder diffraction peaks (°2Θ) at 12.2± 0.1, 14.3± 0.1, 16.2± 0.1, 19.1± 0.1 and 20.6 ± 0.1. 2. The crystal form A of (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide of claim 1, having X-ray powder diffraction peaks (°2Θ) at 8.9± 0.1, 17.9± 0.1, 25.0± 0.1, 28.9± 0.1 and 34.7± 0.1. 3. The crystal form A of (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide of claim 1, wherein the (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide has a water content of from about 4% to about 5%. 4. A pharmaceutical composition comprising the crystal form A of (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide of claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier. 5. A pharmaceutical composition comprising the crystal form A of (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide of claim 2, and a pharmaceutically acceptable adjuvant, diluent or carrier. 6. A pharmaceutical composition comprising the crystal form A of (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide of claim 3, and a pharmaceutically acceptable adjuvant, diluent or carrier. 7. A method for treating an obstructive disease of the airway, comprising orally administering to a patient in need thereof, the pharmaceutical composition of claim 4. 8. A method for treating an obstructive disease of the airway, comprising orally administering to a patient in need thereof, the pharmaceutical composition of claim 5. 9. A method for treating an obstructive disease of the airway, comprising orally administering to a patient in need thereof, the pharmaceutical composition of claim 6. 10. The method of claim 7, wherein the obstructive disease of the airway is bronchiectasis. 11. The method of claim 7, wherein the obstructive disease of the airway is cystic fibrosis. 12. The method of claim 7, wherein the obstructive disease of the airway is asthma. 13. The method of claim 7, wherein the obstructive disease of the airway is chronic obstructive pulmonary disease (COPD). 14. The method of claim 8, wherein the obstructive disease of the airway is bronchiectasis. 15. The method of claim 8, wherein the obstructive disease of the airway is cystic fibrosis. 16. The method of claim 8, wherein the obstructive disease of the airway is asthma. 17. The method of claim 8, wherein the obstructive disease of the airway is chronic obstructive pulmonary disease (COPD). 18. The method of claim 9, wherein the obstructive disease of the airway is bronchiectasis. 19. The method of claim 9, wherein the obstructive disease of the airway is cystic fibrosis. 20. The method of claim 9, wherein the obstructive disease of the airway is asthma. 21. The method of claim 9, wherein the obstructive disease of the airway is chronic obstructive pulmonary disease (COPD).